Enfermedades pulmonares intersticiales difusas - Neumomadrid

19. Etienne B, Bertocchi M, Gamondes JP, et al.
Relapsing pulmonary langerhans cell histiocytosis
after lung transplantation. Am J Respir
Crit Care Med. 1998; 157: 288-91.
20. Vasallo R, Ryu JH, Schroeder DR, et al. Clinical
outcomes of pulmonary Langerhans’ cell
histiocytosis in adults. New Engl J Med. 2002;
346: 484-90.
21. Ryu JH, Moss J, Beck GJ, et al. The NHLBI
lymphangioleiomyomatosis registry. Am J Respir
Crit Care Med. 2006; 173: 105-11.
22. Cohen MM, Pollock-BarZiv S, Johnson SR.
Emerging clinical picture of lymphangioleiomyomatosis.
Thorax. 2005; 60: 875-9.
23. Juvet SC, McCormack FX, Kwiatkowski DJ, et
al. Molecular pathogenesis of lymphangioleiomyomatosis:
lessons learned from orphans.
Am J Respir Cell Moll Biol. 2007; 36: 298-408.
24. Johnson SJ. Lymphangioleiomyomatosis. Eur
Respir J. 2006; 27: 1056-65.
25. Niku S, Stark P, Levin DL, et al. Lymphangioleiomyomatosis.
Clinical, radiologic and pathologic
manifestations. J Thorac Imaging. 2005;
20: 98-102.
26. Ávila NA, Dwyer AJ, Rabel A. CT of pleural
abnormalities in lymphangioleiomyomatosisand
comparison of pleural findings after different
types of pleurodesis. AJR. 1006; 183:
1007-12.
27. Yamauchi M, Nakahara H, Uyama K, et al.
Cytologic finding of chyloascites in lymphangioleiomyomatosis.
A case report. Acta Cytol.
2000; 44: 1081-4.
28. Report of workshop on lymphangioleiomyomnatosis.
Am J Respir Crit Care Med. 1999;
159: 679-83.
29. Johnson JR, Tattersfield AE. Decline in lung
function in lymphangioleiomyomatosis: relation
to menopause and progesterone treatment.
Am J Resir Crit Care Med. 1999; 160:
628-33.
166
V. VILLENA GARRIDO
30. Taveira-DaSilva AM, Stylianou MP, Hedin CJ,
et al. Decline in lung function in patients with
lymphangioleiomyomatosis treated with or
without progesterone. Chest. 2004; 126: 1867-
74.
31. Fremont RD, Milstone AP, Light RW, rt al.
Chylothoraces after lung transplantation for
lymphangioleiomyomatosis: review of the
literature and utilization of a pleurovenous
shunt. J Heart Lung Transplant. 2007; 26: 953-
5.
32. Johnson SR, Whale CI, Hubbard RB, et al. Survival
and disease progression in UK patients
with lymphangioleiomyomatosis. Thorax.
2004; 59: 800-3.
33. Matsui K, Beasley MB, Nelson WK, et al. Prognostic
significance of pulmonary lymphangioleiomyomatosis
histologic score. Am J Surg
Pathol. 2001; 25: 479-84.
34. Lazor R, Valeyre D, Lacronique J, et al. Low
initial KCO predicts rapid FEV1 decline in pulmonary
lymphangioleiomyomatosis. Respir
Med. 2004; 98: 536-41.
35. Gillmore JD, Hawkins PN. Amyloidosis and the
respiratory tract. Thorax. 1999; 54: 444-51.
36. Aylwin ACB, Gishen P, Copley SJ. Imaging appearanceof
thoracic amyloidosis. J Thorac Imaging.
2005; 20: 41-6.
37. Lachmann HJ, HawkinsPN. Amyloidosis and
the lung. Chronic Respir Dis. 2006; 3: 203-
14.
38. Zamora AC, Collard HR, Wolters PJ, et al. Neurofibromatosis-associated
lung disease: a case
series and literature review. Eur Repir J. 2007;
29: 210-4.
39. Lee RE, Yousem SA. Frequency and type of
lung involvement in patients with Gaucher
disease. Lab Invest. 1988; 58: 54A.
40. Marten K, Hansell DM. Inmaging of macrophage-related
lung diseases. Eur Radiol. 2005;
15: 727-41.